OOIR: Observatory of International Research

Papers

(The median citation count of Neurology-Neuroimmunology & Neuroinflammation is 7. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)

Article	Citations
Differential Binding of Autoantibodies to MOG Isoforms in Inflammatory Demyelinating Diseases	150
A 28-Year-Old Woman With Left-Sided Weakness and Atypical MRI Lesions	149
Immunohistologic Features of Cerebral Venous Thrombosis Due to Vaccine-Induced Immune Thrombotic Thrombocytopenia	130
Natalizumab Treatment Induces Proinflammatory CD4 T Cells Preferentially in the Integrin β7+ Compartment	120
Comment: Humoral and T-cell Immunities to SARS-CoV-2 Vaccines: Safety, Efficacy, and Challenges in Autoimmune Neurology	117
Early-Stage Contactin-Associated Protein-like 2 Limbic Encephalitis	105
Relapsing and Immune-Responsive Paroxysmal Jaw Clonus With Blepharospasm and Sialorrhea Associated With D2R Autoantibodies	100
Antibody-Negative Autoimmune Encephalitis	85
CSF Concentrations of CXCL13 and sCD27 Before and After Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis	85
T-Cell Specificity Influences Disease Heterogeneity in Multiple Sclerosis	82
Cortical and Subcortical Dysmetabolism Are Dynamic Markers of Clinical Disability and Course in Anti-LGI1 Encephalitis	72
Longitudinal T-Cell Responses After a Third SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis on Ocrelizumab or Fingolimod	72
Clinical Presentation, Management, and Diagnostic Performance of 2021 Criteria for Paraneoplastic Neurologic Syndromes in Childhood	70
Pro-Inflammatory Molecules Implicated in Multiple Sclerosis Divert the Development of Human Oligodendrocyte Lineage Cells	68
Early Immunotherapy and Longer Corticosteroid Treatment Are Associated With Lower Risk of Relapsing Disease Course in Pediatric MOGAD	67
Relapsing-Remitting Immunotherapy Responsive Small-Fiber Neuropathy	66
Synaptic Protein Loss in Extracellular Vesicles Reflects Brain and Retinal Atrophy in People With Multiple Sclerosis	61
Intrathecal Inflammatory Profile and Gray Matter Damage Predict Progression Independent of Relapse Activity in Early Multiple Sclerosis	61
Should We Measure CSF Complement Levels in Patients With MOGAD?	61
COVID-19 in Patients With Neuromyelitis Optica Spectrum Disorders and Myelin Oligodendrocyte Glycoprotein Antibody Disease in North America	60
Cell-Free DNA Derived From Neutrophils Triggers Type 1 Interferon Signature in Neuromyelitis Optica Spectrum Disorder	59
TNF-Blockade for Primary Stroke Prevention in Adenosine Deaminase 2 Deficiency	55
CXCL10/IgG1 Axis in Multiple Sclerosis as a Potential Predictive Biomarker of Disease Activity	49
Peripheral Immune Profiles Predict ALS Progression in an Age- and Sex-Dependent Manner	48
Acute Paresthesia and Ataxia in a Child	48

Encephalitis and Myelitis in a Young Woman	47
Baicalin Promotes CNS Remyelination via PPARγ Signal Pathway	46
Treatment With Erythropoietin for Patients With Optic Neuritis	46
Patients With Severe Multiple Sclerosis Exhibit Functionally Altered CD8 ⁺ Regulatory T Cells	46
Genome-wide Association Study Identifies 2 New Loci Associated With Anti-NMDAR Encephalitis	45
Timing of MOG-IgG Testing Is Key to 2023 MOGAD Diagnostic Criteria	44
Plasma Biomarkers of Neuropathogenesis in Hospitalized Patients With COVID-19 and Those With Postacute Sequelae of SARS-CoV-2 Infection	44
Toward Precision Phenotyping of Multiple Sclerosis	44
Novel Cell-Based Assay for Alpha-3 Nicotinic Receptor Antibodies Detects Antibodies Exclusively in Autoimmune Autonomic Ganglionopathy	43
Comparative Study of Paraneoplastic and Nonparaneoplastic Autoimmune Encephalitis With GABA _B R Antibodies	43
Immunotherapy-Responsive Neuropathic Pain and Allodynia in a Patient With Glycine Receptor Autoantibodies	43
Increased Intracranial Pressure in Pediatric Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease	43
Retinal Optical Coherence Tomography in Neuromyelitis Optica	43
Trigeminal Nerve Involvement in Bulbar-Onset Anti-IgLON5 Disease	42
Proteomics Analysis Moves the Needle by Generating Clinical Diagnostic Markers	42
Epstein-Barr Virus in the Cerebrospinal Fluid and Blood Compartments of Patients With Multiple Sclerosis and Controls	42
Antineonatal Fc Receptor Antibody Treatment Ameliorates MOG-IgG–Associated Experimental Autoimmune Encephalomyelitis	41
Clinical Manifestations and Treatment Responses in Pediatric Neurofascin 155-IgG4 Autoimmune Nodopathy	41
Clinical Features of Children With MOG-IgG Who Fulfill Criteria of Multiple Sclerosis and Overlapping Disorders	41
The Role of Complement Activation in IgM M-Protein–Associated Neuropathies	41
Blocking Placental Class G Immunoglobulin Transfer Prevents NMDA Receptor Antibody Effects in Newborn Mice	41
Sustained Low Relapse Rate With Highly Variable B-Cell Repopulation Dynamics With Extended Rituximab Dosing Intervals in Multiple Sclerosis	40
B-Cell Compartmental Features and Molecular Basis for Therapy in Autoimmune Disease	40
Antiplexin D1 Antibodies Relate to Small Fiber Neuropathy and Induce Neuropathic Pain in Animals	40
Effect of Prior Treatment With Fingolimod on Early and Late Response to Rituximab/Ocrelizumab in Patients With Multiple Sclerosis	40
Neuropsychological Testing in Autoimmune Encephalitis: A Scoping Review	40
A 42-Year-Old Woman With Rapidly Expanding White Matter Lesions	39
Clinicopathologic Profiles of Sporadic Late-Onset Nemaline Myopathy	38
Absence of Systemic Oxidative Stress and Increased CSF Prostaglandin F2α in Progressive MS	37
miRNA Signature in CSF From Patients With Primary Progressive Multiple Sclerosis	36
Acknowledgment to Reviewers	35
Paraneoplastic Cerebellar Degeneration With P/Q-VGCC vs Yo Autoantibodies	35
Peptides From the Variable Domain of Immunoglobulin G as Biomarkers in Chronic Inflammatory Demyelinating Polyradiculoneuropathy	35
Interim Analysis of Pregnancy Outcomes After Exposure to Dimethyl Fumarate in a Prospective International Registry	34
Cognitive Impairment, Associated Clinical Factors, and MR Volumetric Measures in Myelin Oligodendrocyte Glycoprotein-IgG–Associated Disease	33
Pediatric MOG-Ab–Associated Encephalitis	33
Deep Phenotyping of Neurologic Postacute Sequelae of SARS-CoV-2 Infection	32
“Will the Real Demyelinating Disorder Please Stand Up?”	32
B Cells in the CNS at Postmortem Are Associated With Worse Outcome and Cell Types in Multiple Sclerosis	31
Racial and Ethnic Disparities in the Incidence of Anti-NMDA Receptor Encephalitis	31
Clinical and Immunologic Effects of Paraprobiotics in Long-COVID Patients	31
Modeling MOG Antibody–Associated Disorder and Neuromyelitis Optica Spectrum Disorder in Animal Models	31
Chronic Dengue Virus Encephalitis	31
Cortical Thickness and Serum NfL Explain Cognitive Dysfunction in Newly Diagnosed Patients With Multiple Sclerosis	30
Elsberg Syndrome Secondary to Cytomegalovirus Infection in an Immunocompetent Patient	30
Disease Activity in Pregnant and Postpartum Women With Multiple Sclerosis Receiving Ocrelizumab or Other Disease-Modifying Therapies	30
Recovery From COVID-19 in Multiple Sclerosis	30
Neurologic Manifestations of Common Variable Immunodeficiency	30
Ocrelizumab Extended Interval Dosing in Multiple Sclerosis in Times of COVID-19	29
Alterations in Gut Microbiome-Host Relationships After Immune Perturbation in Patients With Multiple Sclerosis	29

Effect of Previous Disease-Modifying Therapy on Treatment Effectiveness for Patients Treated With Ocrelizumab	29
Cryptococcal Meningitis Reported With Fingolimod Treatment	29
CCR5 Blockade in Inflammatory PML and PML-IRIS Associated With Chronic Inflammatory Diseases' Treatments	29
Distinguishing Transient From Persistent Brain Structural Changes in Pediatric Patients With Acute Disseminated Encephalomyelitis	29
Rituximab Use for Relapse Prevention in Anti-NMDAR Antibody-Mediated Encephalitis	29
Natalizumab Promotes Activation of Peripheral Monocytes in Patients With Multiple Sclerosis	29
Ten Years of Neurology ® Neuroimmunology & Neuroinflammation	29
Clinical Characterization and Ancillary Tests in Susac Syndrome	29
Early Neuroaxonal Damage in Neurologic Disorders Associated With GAD65 Antibodies	29
PET Study of Microglial Activation in Kleine-Levin Syndrome	28
mRNA COVID-19 Vaccination Does Not Exacerbate Symptoms or Trigger Neural Antibody Responses in Multiple Sclerosis	28
Chronic Active Lesions and Larger Choroid Plexus Explain Cognition and Fatigue in Multiple Sclerosis	28
MRI Features and Their Association With Outcomes in Children With Anti-NMDA Receptor Encephalitis	28
Immune Profiling Reveals the T-Cell Effect of Ocrelizumab in Early Relapsing-Remitting Multiple Sclerosis	27
Disease-Modifying Drugs for Multiple Sclerosis and Association With Survival	27
Assessing Commercial Tissue-Based Assays for Autoimmune Neurologic Disorders (I)	27
Retinal Damage and Visual Network Reconfiguration Defines Visual Function Recovery in Optic Neuritis	27
Progressive Encephalomyelopathy in an Older Man	26
HLA-DRB115:01 and the MERTK* Gene Interact to Selectively Influence the Profile of MERTK-Expressing Monocytes in Both Health and MS	26
Disease-Modifying Treatments for Multiple Sclerosis Affect Measures of Cellular Immune Responses to EBNA-1 Peptides	26
Rate of Retinal Layer Thinning as a Biomarker for Conversion to Progressive Disease in Multiple Sclerosis	26
Anti-Hu Antibodies in Patients With Neurologic Side Effects of Immune Checkpoint Inhibitors	26
Early Neuroaxonal Damage in Neurologic Disorders Associated With GAD65 Antibodies	25
Pediatric MOG-Ab–Associated Encephalitis	25
Siponimod Inhibits the Formation of Meningeal Ectopic Lymphoid Tissue in Experimental Autoimmune Encephalomyelitis	25
Area Postrema Syndrome in Autoimmune Glial Fibrillary Acidic Protein Astrocytopathy	24
Prognostic Accuracy of NEDA-3 in Long-term Outcomes of Multiple Sclerosis	24
Neuropsychological Testing in Autoimmune Encephalitis	24
Evaluation of Age-Dependent Immune Signatures in Patients With Multiple Sclerosis	23
Extracellular Vesicle Marker Changes Associated With Disease Activity in Relapsing-Remitting Multiple Sclerosis	23
Ravulizumab and Efgartigimod in Myasthenia Gravis	23
CAR-T Cell–Mediated B-Cell Depletion in Central Nervous System Autoimmunity	22
SARS-CoV-2–Specific Immune Responses in Patients With Postviral Syndrome After Suspected COVID-19	22
Cerebellar Ataxia With Anti-DNER Antibodies	22
Presentation and Outcome in S1P-RM and Natalizumab-Associated Progressive Multifocal Leukoencephalopathy	22
Visually Evoked Potential as Prognostic Biomarker for Neuroaxonal Damage in Multiple Sclerosis From a Multicenter Longitudinal Cohort	22
Multiple Sclerosis Disease Activity and Disability Following Cessation of Fingolimod for Pregnancy	22
CNS Antigen-Specific Neuroinflammation Attenuates Ischemic Stroke With Involvement of Polarized Myeloid Cells	22
Different Complement Activation Patterns Following C5 Cleavage in MOGAD and AQP4-IgG+NMOSD	21
Association of NEDA-4 With No Long-term Disability Progression in Multiple Sclerosis and Comparison With NEDA-3	21
Inflammatory Activity After Diverse Fertility Treatments	21
Imaging Characteristics of Choroid Plexuses in Presymptomatic Multiple Sclerosis	21
Mutational Profile in 75 Patients With Anti–Myelin-Associated Glycoprotein Neuropathy	21
Progressive Myelitis in a 63-Year-Old Woman	21
Mitoxantrone in NMO Spectrum Disorder in a Large Multicenter Cohort in French Caribbean	21
Antibody Investigations in 2,750 Children With Suspected Autoimmune Encephalitis	21
Familial History of Autoimmune Disorders Among Patients With Pediatric Multiple Sclerosis	20
Microstructural Damage and Repair in the Spinal Cord of Patients With Early Multiple Sclerosis and Association With Disability at 5 Years	20
A 79-Year-Old Woman With Worsening Headaches and Pachymeningeal Enhancement	20
Single-Cell Multi-Omics Map of Cell Type–Specific Mechanistic Drivers of Multiple Sclerosis Lesions	20
Serological Markers of Clinical Improvement in MuSK Myasthenia Gravis	20
Siponimod Inhibits the Formation of Meningeal Ectopic Lymphoid Tissue in Experimental Autoimmune Encephalomyelitis	20
Retinal Changes in Double-Antibody Seronegative Neuromyelitis Optica Spectrum Disorders	20
Neuromyelitis Optica Spectrum Disorders in Africa	20
Immune Checkpoint Inhibition–Related Myasthenia-Myositis-Myocarditis Responsive to Complement Blockade	20
Temporal Lobe Epilepsy Associated With Glutamic Acid Decarboxylase Antibodies	20
Increased NLRP3 Inflammasome Activation and Pyroptosis in Patients With Multiple Sclerosis With Fingolimod Treatment Failure	20
Dynamics of Retinal Vessel Loss After Acute Optic Neuritis in Patients With Relapsing Multiple Sclerosis	20
Neurofilament Light in CSF and Plasma Is a Marker of Neuronal Damage in HTLV-1–Associated Myelopathy and Correlates With Neuroinflammation	20
Identification of Distinct Biological Groups of Patients With Cryptogenic NORSE via Inflammatory Profiling	20
Dimethyl Fumarate Reduces Inflammation in Chronic Active Multiple Sclerosis Lesions	19
COVID-19 Vaccination Reactogenicity in Persons With Multiple Sclerosis	19
COVID-19 Severity in Multiple Sclerosis	19
Combined Treatment With Pembrolizumab and Allogenic BK Virus-Specific T Cells in Progressive Multifocal Leukoencephalopathy	19
Neurofilament Light Chain as a Discriminator of Disease Activity Status in MOG Antibody-Associated Disease	19
Autopsy Case of Meningoencephalomyelitis Associated With Glial Fibrillary Acidic Protein Antibody	19
Comparison of Structural Changes in Nodding Syndrome and Other Epilepsies Associated With Onchocerca volvulus	19
Multiple Sclerosis Patient Macrophages Impaired Metabolism Leads to an Altered Response to Activation Stimuli	19
Seizure Semiology in Antibody-Associated Autoimmune Encephalitis	19
Dramatic Response to Anti-IL-6 Receptor Therapy in Children With Life-Threatening Myelin Oligodendrocyte Glycoprotein-Associated Disease	19
Primary Angiitis of the CNS	18
The Inner Nuclear Layer in Pediatric Multiple Sclerosis	18
Reemerging Infectious Diseases and Neuroimmunologic Complications	18
Human Leukocyte Antigen Association Study Reveals DRB104:02 Effects Additional to DRB107:01 in Anti-LGI1 Encephalitis	18
Microglia as Central Protagonists in the Chronic Stress Response	18
Association Between Sun Exposure and Risk of Relapse in Pediatric-Onset Multiple Sclerosis	18
B-Cell Reconstitution After Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis	18
Neurofilament Light Chain Levels in Multiple Sclerosis Correlate With Lesions Containing Foamy Macrophages and With Acute Axonal Damage	18
Prolonged Corticosteroids Without Maintenance Immunotherapy for Treatment of Anti-LGI1 Encephalitis	18
Intrathecal CD8 ⁺ CD20 ⁺ T Cells in Primary Progressive Multiple Sclerosis	17

Impact of COVID-19 in Immunosuppressed Children With Neuroimmunologic Disorders	17
COVID-19 Infection in Fingolimod- or Siponimod-Treated Patients	17
Decrease in Serum Anti-MAG Autoantibodies Is Associated With Therapy Response in Patients With Anti-MAG Neuropathy	17
Targeted RNA Sequencing of VZV-Infected Brain Vascular Adventitial Fibroblasts Indicates That Amyloid May Be Involved in VZV Vasculopathy	17
Modern Look at Transverse Myelitis and Inflammatory Myelopathy	17
Cardiac Involvement in Neurosarcoidosis	17
SARS-CoV-2 Vaccines and Multiple Sclerosis	17
Cenobamate and Clobazam Combination as Personalized Medicine in Autoimmune-Associated Epilepsy With Anti-Gad65 Antibodies	17
CSF Parvalbumin Levels at Multiple Sclerosis Diagnosis Predict Future Worse Cognition, Physical Disability, Fatigue, and Gray Matter Damage	16
CLMP Promotes Leukocyte Migration Across Brain Barriers in Multiple Sclerosis	16
Immune Repertoire Profiling Reveals Its Clinical Application Potential and Triggers for Neuromyelitis Optica Spectrum Disorders	16
Immune and Genetic Signatures of Breast Carcinomas Triggering Anti-Yo–Associated Paraneoplastic Cerebellar Degeneration	16
Central Vein Sign Profile of Newly Developing Lesions in Multiple Sclerosis	16
Obesity Affects Disease Activity and Progression, Cognitive Functioning, and Quality of Life in People With Multiple Sclerosis	16
Primary Angiitis of the CNS	16
Antibodies Against Glutamic Acid Decarboxylase 65 Are Locally Produced in the CSF and Arise During Affinity Maturation	16
MOG Antibody–Associated Disease in the Setting of Metastatic Melanoma Complicated by Immune Checkpoint Inhibitor Use	16
Longitudinal T-Cell Responses After a Third SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis on Ocrelizumab or Fingolimod	16
Membrane Proteome-Wide Screening of Autoantibodies in CIDP Using Human Cell Microarray Technology	16
Retrospective Pediatric Cohort Study Validates NEOS Score and Demonstrates Applicability in Children With Anti-NMDAR Encephalitis	16
Multiple Sclerosis	16
Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease Presenting as Intracranial Hypertension	16
Role of Chitinase 3–like 1 as a Biomarker in Multiple Sclerosis	16
Isolated Memory Loss in Anti-NMDAR Encephalitis	15
Neurology® Neuroimmunology & Neuroinflammation Acknowledgment to Reviewers	15
Innate Immune Cell–Related Pathology in the Thalamus Signals a Risk for Disability Progression in Multiple Sclerosis	15
Phenotypic Insights Into Anti-IgLON5 Disease in IgLON5-Deficient Mice	15
Electrolyte Imbalance in Anti LGI1 Encephalitis	15
Antibodies Produced by CLL Phenotype B Cells in Patients With Myasthenia Gravis Are Not Directed Against Neuromuscular Endplates	15
Broad Analysis of Serum and Intrathecal Antimicrobial Antibodies in Multiple Sclerosis Underscores Unique Role of Epstein-Barr Virus	15
Risk of Getting COVID-19 in People With Multiple Sclerosis	15
Retinal Optical Coherence Tomography Longitudinal Measures as Prognostic Biomarkers in Multiple Sclerosis	15
Acknowledgment to Reviewers	15
Leveraging Visual Outcome Measures to Advance Therapy Development in Neuroimmunologic Disorders	15
Therapies in Stiff-Person Syndrome	15
Influence of Previous Disease-Modifying Drug Exposure on T-Lymphocyte Dynamic in Patients With Multiple Sclerosis Treated With Ocrelizumab	14
MRI Characteristics of Autoimmune Encephalitis With Autoantibodies to GABAA Receptor: A Case Series	14
Acknowledgment to Reviewers	14
CNS Lymphocytic Vasculitis in a Young Woman With COVID-19 Infection	14
Association of Vitamin D Polygenic Risk Scores and Disease Outcome in People With Multiple Sclerosis	14
Pregnancy and Infant Outcomes in Women With Multiple Sclerosis Treated With Ocrelizumab	14
Serum Biomarker Profiles Discriminate AQP4 Seropositive and Double Seronegative Neuromyelitis Optica Spectrum Disorder	14
Early Reduction of MRI Activity During 6 Months of Cladribine Tablet Treatment for Highly Active Relapsing Multiple Sclerosis: MAGNIFY-MS	14
Nodular Pachymeningitis Associated With Relapsing Polychondritis and Crohn Disease Responsive to Adalimumab and Prednisone	14
Visual System Involvement in Glial Fibrillary Acidic Protein Astrocytopathy	14
Evolution of Chronic Lesion Tissue in Relapsing-Remitting Patients With Multiple Sclerosis	13
The Aryl Hydrocarbon Receptor–Dependent TGF-α/VEGF-B Ratio Correlates With Disease Subtype and Prognosis in Multiple Sclerosis	13
The Effect of Smoking on Long-term Gray Matter Atrophy and Clinical Disability in Patients with Relapsing-Remitting Multiple Sclerosis	13
Novel Approaches to Treatment of Immune-Mediated Chronic Intestinal Pseudo-Obstruction	13
The OSCAR-MP Consensus Criteria for Quality Assessment of Retinal Optical Coherence Tomography Angiography	13
Safety and Dose-Response of Vidofludimus Calcium in Relapsing Multiple Sclerosis	13
International Delphi Consensus on the Management of AQP4-IgG+ NMOSD	13
Multiple Sclerosis, Disease-Modifying Therapies, and Infections	13
Analysis of Macrophages and Peptidergic Fibers in the Skin of Patients With Painful Diabetic Polyneuropathy	13
White Matter Tract Degeneration in Multiple Sclerosis Patients With Progression Independent of Relapse Activity	13
A New England COVID-19 Registry of Patients With CNS Demyelinating Disease	12
Occurrence and Severity of Coronavirus Disease 2019 Are Associated With Clinical Disability Worsening in Patients With Multiple Sclerosis	12
Serum Proteomics Distinguish Subtypes of NMO Spectrum Disorder and MOG Antibody-Associated Disease and Highlight Effects of B-Cell Depletion	12
Serum Contactin-1 in CIDP	12
Trajectories of Inflammatory Markers and Post–COVID-19 Cognitive Symptoms	12
Relapsing White Matter Disease and Subclinical Optic Neuropathy	12
Alterations of Thymus-Derived Tregs in Multiple Sclerosis	12
Late-Onset Anti-GABA _B Receptor Encephalitis	12
Analysis of Macrophages and Peptidergic Fibers in the Skin of Patients With Painful Diabetic Polyneuropathy	12
Risk HLA Variants Affect the T-Cell Repertoire in Multiple Sclerosis	12
Acute Optic Neuropathy in Older Adults	12
Aseptic Neutrophilic Meningitis With Hypoglycorrhachia Following a Single Ocrelizumab Infusion	12
Vulnerability of Thalamic Nuclei at CSF Interface During the Entire Course of Multiple Sclerosis	12
Pachymeningitis in Biopsy-Proven Sarcoidosis	12
Impact of Immune Checkpoint Inhibitors on the Course of Multiple Sclerosis	12
CSF Chitinase 3–Like 2 Is Associated With Long-term Disability Progression in Patients With Progressive Multiple Sclerosis	11
Long-term Effectiveness of IVIg Maintenance Therapy in 36 Patients With GAD Antibody–Positive Stiff-Person Syndrome	11
CNS Inflammation as the First Sign of Complement Factor I Deficiency	11
Defining the Clinicoradiologic Syndrome of SARS-CoV-2 Acute Necrotizing Encephalopathy	11
GRP78 Antibodies Are Associated With Blood-Brain Barrier Breakdown in Anti–Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disorder	11
Baseline Microglial Activation Correlates With Brain Amyloidosis and Longitudinal Cognitive Decline in Alzheimer Disease	11
International Consensus Recommendations for the Treatment of Pediatric NMDAR Antibody Encephalitis	11
Frequency of Asymptomatic Optic Nerve Enhancement in 203 Patients With MOG Antibody-Associated Disease	11
Post-COVID Small Fiber Neuropathy, Implications of Innate Immunity, and Challenges on IVIG Therapy	11
Assessing Commercial Tissue-Based Assays for Autoimmune Neurologic Disorders (II)	11
Serum Neurofilament Light Chain as a Biomarker for CIDP Diagnosis, Severity, and Treatment Outcome	11
CSF Findings in Acute NMDAR and LGI1 Antibody–Associated Autoimmune Encephalitis	11
Corrections to Preprint Server Information	10
Micro-RNA Signature in CSF Before and After Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis	10
Structural Changes of Cutaneous Immune Cells in Patients With Type 1 Diabetes and Their Relationship With Diabetic Polyneuropathy	10
Acute Disseminated Encephalomyelitis and Acute Hemorrhagic Leukoencephalitis Following COVID-19	10
Clinical Outcome Assessments in Encephalitis	10
Multiple Sclerosis CSF Is Enriched With Follicular T Cells Displaying a Th1/Eomes Signature	10
Teriflunomide Promotes Oligodendroglial 8,9-Unsaturated Sterol Accumulation and CNS Remyelination	10
Anti-C2 Antibody ARGX-117 Inhibits Complement in a Disease Model for Multifocal Motor Neuropathy	10
Prevalence, Clinical Profiles, and Prognosis of Stiff-Person Syndrome in a Japanese Nationwide Survey	10
Melanoma Cell Adhesion Molecule Expressing Helper T Cells in CNS Inflammatory Demyelinating Diseases	10
Long-term Effects of IL-6 Receptor Blockade Therapy on Regulatory Lymphocytes and Neutrophils in Neuromyelitis Optica Spectrum Disorder	9
Comparative Effects of Domain-Specific Human Monoclonal Antibodies Against LGI1 on Neuronal Excitability	9
Humoral and Cellular Responses to SARS-CoV-2 in Convalescent COVID-19 Patients With Multiple Sclerosis	9